Filing Flows › United Therapeutics (UTHR) › Operating margin
United Therapeutics (UTHR) operating margin by quarter
United Therapeutics' operating margin was 37.0% in Q3 2026 (third quarter 2026), -5.3 pts from Q2 2026. Over the last 7 quarters it ranged from 37.0% (Q3 2026) to 48.6% (Q3 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 37.0% | -5.3 pts | -11.6 pts |
| Q2 2026 | 42.2% | +0.5 pts | -3.4 pts |
| Q1 2026 | 41.7% | -3.5 pts | -6.5 pts |
| Q4 2025 | 45.1% | -3.5 pts | — |
| Q3 2025 | 48.6% | +3.0 pts | — |
| Q2 2025 | 45.6% | -2.5 pts | — |
| Q1 2025 | 48.2% | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' operating margin?
United Therapeutics' operating margin was 37.0% in Q3 2026 (third quarter 2026), -5.3 pts from Q2 2026.
How has United Therapeutics' operating margin changed?
Over the last 7 quarters it ranged from 37.0% (Q3 2026) to 48.6% (Q3 2025).